Role of Antibody Signaling in Inducing Tumor Dormancy
Cancer dormancy is a well-recognized clinical phenomenon in which tumor cells are present, but the tumor burden does not increase for long periods of time1–3. However, tumor cells can regrow many years later. In breast cancer, there is a steady rate of recurrence 10 to 20 years after removal of the primary tumorl3,4 and the recurrent tumor frequently grows at a rapid rate(5). A particularly pertinent example is the low grade (follicular) form of non-Hodgkin’s lymphoma (NHL) in which long-term remissions are common but, eventually, virtually all die of a recurrence. Levy and Miller(5) have treated such patients with monoclonal anti-idiotype (Id) and have achieved remissions in a high proportion of patients. Relapses, many caused by Id-negative variants, are frequent indicating that the antibody (Ab) was particularly effective in inducing dormancy in cells bearing the corresponding idiotope but that hypermutation of VH and VL genes eventually allow some tumor cells from the original clone to escape(5–7).
KeywordsCell Cycle Arrest Lymphoma Cell SCID Mouse Daudi Cell Tumor Dormancy
Unable to display preview. Download preview PDF.
- 2.Meltzer, A. Dormancy and breast cancer. J. Surg. Oncol. 43: 181–188, 1990.Google Scholar
- 3.Berkowitz, H., F. Rosata, and C.P. Neiby. Late recurrence of carcinoma of breast: Case report and literature survey. Amer. Surg. 32: 287–289, 1966.Google Scholar
- 4.Henderson, I.C., J.R. Harris, D.W. Kinne, and S. Hellman. Cancer of the breast. IN: Cancer: Principles and Practice of Oncology (VT. DeVita, Jr., S. Hellman, and S.A. Rosenberg, Eds.), Philadelphia: J.B. Lippincott, pp. 1197–1268, 1989.Google Scholar
- 5.Levy, R. and A.R. Miller. Therapy of lymphoma directed at idiotypes. Monographs. J. Natl. Cancer Inst. 10: 61–68, 1990.Google Scholar
- 6.Meeker, T., J. Lowder, M.L. Cleary, S. Stewart, R. Warnke, J. Sklar, and R. Levy. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 312: 1658–1665, 1985.Google Scholar
- 8.Uhr, J.W., T. Tucker, R.D. May, H. Siu, and E.S. Vitetta. Cancer dormancy: Studies of the murine BCL1 lymphoma. Cancer Res. 51: 50455–50535, 1991.Google Scholar
- 10.Racila, E., R.H. Scheuermann, L.J. Picker, E. Yefenof, T. Tucker, W. Chang, R. Marches, N.E. Street, E.S. Vitetta, and J.W. Uhr. Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J. Exp. Med. 181: 1539–1550, 1995.PubMedCrossRefGoogle Scholar
- 12.Marches, R., E. Racila, T.F. Tucker, L. Picker, P. Mongini, R. Hsueh, R.H. Scheuermann, and J.W. Uhr. Tumor dormancy and cell signaling. III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Therap. Immunol., in press,1995.Google Scholar
- 15.Hasbold, J. and G.G.B. Klaus. Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas. Eur. J. Immunol. 20: 1685–1690, 1990.Google Scholar
- 16.Parry, S.L., M.J. Holman, J. Hasbold, and G.G.B. Klaus. Plastic-immobilized anti-Is or anti-6 antibodies induce apoptosis in mature murine B lymphocytes. Eur. J. Immunol. 24: 974–979, 1994.Google Scholar
- 26.Brunner, T., R.J. Mogil, D. LaFace, N.J. Yoo, A. Mahboubi, F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, C.F. Ware, and D.R. Green. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373: 441–444, 1995.PubMedCrossRefGoogle Scholar
- 28.Racila, E., R. Hsueh, R. Marches, T.F. Tucker, P.H. Krammer, R.H. Scheuermann, and J.W. Uhr. Tumor dormancy and cell signaling. IV. Anti-p induced apoptosis in human B lymphoma cells is not caused by an APO-1 - APO-1 ligand interaction. Proc. Natl. Acad. Sci. USA, in press,1995.Google Scholar